Clinical Effects and Safety of Rituximab for Treatment of Refractory Pediatric Autoimmune Diseases

Journal of Pediatrics

Volumn 150, Issue 4, 2007, Pages 376-382

  El Hallak, Moussa ^a   Binstadt, Bryce A ^a   Leichtner, Alan M ^a   Bennett, Carolyn M ^a   Neufeld, Ellis J ^a   Fuhlbrigge, Robert C ^a   Zurakowski, David ^a   Sundel, Robert P ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; CANDIDIASIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HEADACHE; HERPES; HUMAN; HYPOTENSION; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; KERATITIS; LABORATORY TEST; LUNG INFECTION; LYMPHOCYTE COUNT; MALE; MORTALITY; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY HEALTH CARE; THROAT IRRITATION; VASCULITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; INFECTION; INFUSIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; TREATMENT OUTCOME;

EID: 33947216588     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.10.067     Document Type: Article

References (37)

1. Noorchashm H., Noorchashm N., Kern J., Rostami S.Y., Barker C.F., and Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46 (1997) 941-946
2. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., and Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189 (1999) 1639-1648
3. Takemura S., Braun A., Crowson C., Kurtin P.J., Cofield R.H., O'Fallon W.M., et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167 (2001) 1072-1080
4. O'Neill S.K., Shlomchik M.J., Glant T.T., Cao Y., Doodes P.D., and Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 174 (2005) 3781-3788
5. Wallace C.A., and Sherry D.D. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 19 (1992) 1604-1607
6. Reiff A., Shaham B., Wood B.P., Bernstein B.H., Stanley P., and Szer I.S. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 13 (1995) 113-118
7. Balint G., and Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm Res 45 (1996) S91-S95
8. Flato B., Vinje O., and Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin Rheumatol 17 (1998) 505-510
9. Looney R.J. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 61 (2002) 863-866
10. Virgolini L., and Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 58 (2004) 299-309
11. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., and Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63 (1984) 1424-1433
12. Einfeld D.A., Brown J.P., Valentine M.A., Clark E.A., and Ledbetter J.A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7 (1988) 711-717
13. Valentine M.A., Meier K.E., Rossie S., and Clark E.A. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C. J Biol Chem 264 (1989) 11282-11287
14. Gopal A.K., and Press O.W. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 134 (1999) 445-450
15. Edwards J.C., Cambridge G., and Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology 97 (1999) 188-196
16. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40 (2001) 205-211
17. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
18. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52 (2005) 601-607
19. Specks U., Fervenza F.C., McDonald T.J., and Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44 (2001) 2836-2840
20. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
21. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
22. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
23. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Hematol 72 (2004) 79-88
24. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31 (2005) 456-473
25. Tsutsumi Y., Kanamori H., Mori A., Tanaka J., Asaka M., Imamura, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4 (2005) 599-608
26. Bennett C.M., Rogers Z.R., Kinnamon D.D., Bussel J.B., Mahoney D.H., Abshire T.C., et al. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood (2005) Dec 13 [Epub ahead of print].
27. Binstadt B.A., Caldas A.M., Turvey S.E., Stone K.D., Weinstein H.J., Jackson J., et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 143 (2003) 598-604 Erratum in: J Pediatr 2004;144:558.
28. National Cancer Institute, Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, accessible at http://ctep.cancer.gov/reporting/ctcnew.html.
29. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., and Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358 (2001) 1511-1513
30. Zecca M., Nobili B., Ramenghi U., Perrotta S., Amendola G., Rosito P., et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101 (2003) 3857-3861
31. Wang J., Wiley J.M., Luddy R., Greenberg J., Feuerstein M.A., and Bussel J.B. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 146 (2005) 217-221
32. Fox R.A., Neufeld E.J., and Bennett C.M. Rituximab for adolescents with hemophilia and high titer inhibitors. Haemophilia 12 (2006) 218-222
33. Shaw T., Quan J., and Totoritis M.C. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 62 (2003) ii55-ii59
34. McLaughlin P., Hagemeister F.B., and Grillo-Lopez A.J. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26 (1999) S79-S87
35. Plosker G.L., and Figgitt D.P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63 (2003) 803-843
36. Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M.R., Salden M., Bodman-Smith M., and Webster A.D. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48 (2003) 2146-2154
37. Bennett C.M., de Jong J.L., and Neufled E.J. Targeted ITP strategies: do they elucidate the biology of ITP and related disorders?. Pediatr Blood Cancer 47 5 Suppl (2006) 706-709